Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2011-05-10
2011-05-10
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S021200, C514S019300, C514S010300, C435S069700
Reexamination Certificate
active
07939056
ABSTRACT:
The present invention is directed to methods for the treatment of adenocarcinomas that are characterized by the overexpression of a particular oncogene, Pim-1. The procedure involves administering a therapeutically effective amount of interleukin-10 that has been coupled to a carrier that increases its circulating plasma half-life.
REFERENCES:
patent: 5368854 (1994-11-01), Rennick
patent: 6403077 (2002-06-01), Strom et al.
patent: 6410008 (2002-06-01), Strom et al.
patent: 2002/0173628 (2002-11-01), Strom et al.
patent: 2003/0026778 (2003-02-01), Strom et al.
patent: 2003/0109690 (2003-06-01), Ruben et al.
patent: WO 02/077033 (2002-10-01), None
Kim et al., Oncogene, Mar. 11, 2004, vol. 23(10):1838-1844.
Berman et al., J. Immunol., 1996, vol. 157:231-238.
Khosravi-Far et al., cancer Metastasis Rev., 1994, vol. 13(1):67-89.
Colombel, et al., “Interleukin 10 (Tenovil) in the Prevention of Postoperative Recurrence of Crohn's Disease,”Gut49:42-46 (2001).
Erdman, et al., “CD4+CD25+Regulatory T Lymphocytes Inhibit Microbially Induced Colon Cancer in Rag2-Deficient Mice,”Am. J. Pathol. 162:691-702 (Feb. 2003).
Erdman, et al., CD4+CD25+Regulatory Lymphocytes Require Interleukin 10 to Interrupt Colon Carcinogens in Mice1, Cancer Res. 63:6042-6050 (Sep. 2003).
Erdman, et al., CD4+CD25+Regulatory Lymphocytes Induce Regression of Intestinal Tumors inApcMini+Mice,Cancer Res. 65:3998-4004 (May 2005).
Fedorak, et al., “Recombinant Human Interluekin 10 in the Treatment of Patients With Mild to Moderately Active Crohn's Disease,”Gastroenterology119:1473-1482 (2000).
Fiorentino, et al., “Two Types of Mouse T Helper Cell IV,”J. Exp. Med.170:2081-2089 (Dec. 1989).
Fiorentino, et al., “IL-10 Inhibits Cytokine Production by Activated Macrophages1,”J. Immunol. 147:3815-3822 (Dec. 1991).
Flores-Villanueva, et al., “Recombinant IL-10 and IL10/Fc Treatment Down-Regulate Egg Antigen-Specific Delayed Hypersensitivity Reactions and Egg Granuloma Formation in Schistosomiasis,”J. Immunol.156:3315-3320 (1996).
Gerard, et al., “Interleukin 10 Reduces the Release of Tumor Necrosis Factor and Prevents Lethality in Experimental Endotoxemia, ”J. Exp. Med.177:547-550 (Feb. 1993).
Kim, et al., “Synergism of Cytoplasmic Kinases in IL6-Induced Ligand-Independent Activation of Androgen Receptor in Prostate Cancer Cells,”Oncogene23:1838-1844 (2004).
Li, et al., “IL-10 and It's Related Cytokines for Treatment of Inflammatory Bowel Disease,”World J. Gastroenterol.10(5):620-625 (2004).
Maloy, et al., “CD4+CD25+TRCells Suppress Innate Immune Pathology Through Cytokine-Dependent Mechanisms,”J. Exp. Med.197:111-119 (Jan. 2003).
Mihara, et al., “CTLA4Ig Inhibits T-Cell Dependent B-Cell Maturation in Murine Systemic Lupus Erythematosus,”J. Clin. Invest. 106:91-101 (Jul. 2000).
Moore, et al., “Interleukin-10 and the Interleukin-10 Receptor,”Annu. Rev. Immunol. 19:683-765 (2001).
Moore, et al., “Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI,”Science248:1230-1234 (Jun. 1990).
O'Garra, et al., “Production of Cytokines by Mouse B Cells: B Lymphomas and Normal B Cells Produce Interleukin 10,”Internat. Immunol. 2:821-832 (1990).
Powrie, et al., “T Cells in Inflammatory Bowel Disease: Protective and Pathogenic Roles,”Immunity3:171-174 (Aug. 1995).
Powrie, et al., “Regulating the Regulators,”Science299:1030-1031 (Feb. 2003).
Schreiber, et al., “Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease,”Gastroenterology119:1461-1472 (2000).
Van Deventer, et al., “Multiple Doses of Intravenous Interleukin 10 in Steroid-Refractory Crohn's Disease,”Gastroenterology113:383-389 (1997).
Viera, et al., “Isolation and Expression of Human Cytokine Synthesis Inhibitory Factor cDNA clones: Homology to Epstein-Barr Virus Open Reading Frame BCRF1,”Proc. Natl. Acad. Sci. USA88:1172-1176 (Feb. 1991).
Zheng, et al., “A Noncytolytic IL-10/Fc Fusion Protein Prevents Diabetes, Blocks Autoimmunity, and Promotes Suppressor Phenomena in NOD Mice1,”J. Immunol. 158:4507-4513 (1997).
Zheng, et al., “Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharied-Induced Septic Shock and Allogeneic Islet Transplantation1,”J. Immunol. 154:5590-5600 (1995).
International Preliminary Report on Patentability for PCT/US06/43900 filed Nov. 13, 2006.
International Search Report for PCT/US06/43900 filed Nov. 13, 2006.
Written Opinion of the International Searching Authority for PCT/US06/43900 filed Nov. 13, 2006.
Davidson Anne
Erdman Susan
Fox James
Horwitz Bruce
Kemmerer Elizabeth C.
Law Office of: Michael A. Sanzo, LLC
The Brigham and Women's Hospital, Inc.
Xie Xiaozhen
LandOfFree
Interleukin-10 compositions for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-10 compositions for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-10 compositions for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633150